| Followers | 12 |
| Posts | 421 |
| Boards Moderated | 0 |
| Alias Born | 09/29/2010 |
Sunday, February 06, 2011 2:15:43 PM
I understand that it is already being sold. Right now, Spectral has a clinical trial in the US for the Toray device for patients with Endotoxemia and Septic Shock. In the trial one of the patient's inclusion criteria is "Endotoxin Activity Assay = 0.60 EAA units" which is where their EAA test would come in.
What I don't understand is if the Toray device is a critical care device. To hook a patient up, they would need to be in the ICU. After hook up, do the Toray patients get moved out of the ICU and into the normal ward? Does that make sense? From what I understand, I think Toraymyxin requires trained staff for hookup which can include the ICU. But the ICU will only accept severe sepsis patients. I guess I'm confused of how the Toray device gets used and the role of the ICU, the balance between the two. If a Spectral patient have Endotoxemia, are they allowed in the ICU? For Septic Shock, I think they are allowed?
Dr Chan's explanation:
"Going back to Toraymyxin, it would be improbable or impossible to use Toraymyxin in an outpatient setting. It would even be problematic to use this in the emergency room, as the emergency room's role in severe sepsis is to give antibiotics, stabilize and triage the patient...not to treat definitively. By the time a patient reaches the intensive care unit, it is likely too late to use Toraymyxin, as the problem is much more about cytokine storm than endotoxemia. But for CytoSorb, as a highly efficient cytokine filter, this is a perfect time and place to intervene. "
What I don't understand is if the Toray device is a critical care device. To hook a patient up, they would need to be in the ICU. After hook up, do the Toray patients get moved out of the ICU and into the normal ward? Does that make sense? From what I understand, I think Toraymyxin requires trained staff for hookup which can include the ICU. But the ICU will only accept severe sepsis patients. I guess I'm confused of how the Toray device gets used and the role of the ICU, the balance between the two. If a Spectral patient have Endotoxemia, are they allowed in the ICU? For Septic Shock, I think they are allowed?
Dr Chan's explanation:
"Going back to Toraymyxin, it would be improbable or impossible to use Toraymyxin in an outpatient setting. It would even be problematic to use this in the emergency room, as the emergency room's role in severe sepsis is to give antibiotics, stabilize and triage the patient...not to treat definitively. By the time a patient reaches the intensive care unit, it is likely too late to use Toraymyxin, as the problem is much more about cytokine storm than endotoxemia. But for CytoSorb, as a highly efficient cytokine filter, this is a perfect time and place to intervene. "
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 11:00:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 11:04:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:27:51 PM
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/25/2026 08:05:00 PM
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 • PR Newswire (US) • 03/19/2026 01:44:00 PM
- CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/05/2026 12:00:00 PM
- CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update • PR Newswire (US) • 01/12/2026 12:00:00 PM
- CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 02:09:45 AM
- Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/17/2025 10:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:34:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:32:19 PM
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update • PR Newswire (US) • 11/13/2025 09:05:00 PM
- CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/11/2025 12:00:00 PM
- CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 10/30/2025 11:00:00 AM
- In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer • PR Newswire (US) • 10/28/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2025 08:20:54 PM
- CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen • PR Newswire (US) • 09/29/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2025 08:35:38 PM
- CytoSorbents Provides DrugSorb-ATR Regulatory Update • PR Newswire (US) • 09/16/2025 11:00:00 AM
- CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day • PR Newswire (US) • 09/08/2025 11:00:00 AM
- CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference • PR Newswire (US) • 09/05/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 08:05:59 PM
- CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR • PR Newswire (US) • 08/20/2025 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2025 07:47:54 PM
